Journal of Literature Pharmacy Sciences

Therapeutic Applications of Ginkgo biloba L. Tree: Systemic Review
Ginkgo biloba L. Ağacının Terapötik Uygulamaları: Sistematik Derleme
Sena ÖZTÜRKa, Aynur SARIa
aDepartment of Pharmacognosy, İstanbul University Faculty of Pharmacy, İstanbul, Türkiye
J Lit Pharm Sci. 2023;12(1):31-42
doi: 10.5336/pharmsci.2022-91528
Article Language: EN
Full Text
ABSTRACT
 Ginkgo biloba L. is considered one of the oldest trees in the world and has been used for thousands of years for its variety of pharmacological effects. It is commonly known as ginkgo. Leaf extracts of this fossil tree have been standardized and patented under the name EGb761. EGb761 mainly consists of terpene trilactones which are unique to this species and flavone glycosides. It is supported by scientific research that these chemical components are responsible for the pharmacological effects of the tree. G. biloba L. has gained interest as a therapeutic plant for its favorable effects in cognitive impairment and neurodegenerative disorders like dementia. Its beneficial impacts on a wide range of pathological conditions, including cardiovascular health, asthma, psychiatric disorders, skin problems, and glaucoma as well as antioxidant, anti-inflammatory, anticancer and hepatoprotective activities, have been reported through experimental and clinical research. Ginkgo is generally well tolerated but when combined with warfarin or other antiplatelet medications, it can increase the risk of bleeding. This review mainly focuses on recent studies of pharmacological effects of G. biloba L. and indicates that G. biloba L. might be beneficial in the prevention and improvement of neurological, cardiovascular, pulmonary, ocular, metabolic, mental disorders also have anticancer and antimicrobial properties however further studies and clinical trials are necessary to confirm the safety and efficacy of G. biloba L. in order to guide medical use.

Keywords: Ginkgo biloba; EGb761; ginkgolides; ginkgolic acid; pharmacological activity
ÖZET
 Ginkgo biloba L., dünyanın en eski ağaçlarından biri olarak kabul edilir ve çeşitli farmakolojik etkileri nedeniyle binlerce yıldır kullanılmaktadır. Genellikle ginkgo olarak bilinmektedir. Bu fosil ağacın kendine has yapraklarının ekstreleri standardize edilmiş ve EGb761 adı ile patent almıştır. EGb761 esas olarak terpen trilaktonlar ve flavon glikozitlerinden oluşur, G. biloba ağacının farmakolojik etkilerinden bu kimyasal bileşenlerin sorumlu olduğu bilimsel araştırmalarla desteklenmektedir. G. biloba L., bilişsel bozulma ve bunama gibi nörodejeneratif bozukluklarda olumlu etkileri nedeniyle terapötik bir bitki olarak ilgi görmüştür. Kardiyovasküler sağlık, astım, psikiyatrik bozukluklar, cilt sorunları ve glokom dâhil olmak üzere çok çeşitli patolojik durumlar üzerindeki yararlı etkilerinin yanı sıra antioksidan, antiinflamatuar, antikanser ve hepatoprotektif aktiviteleri deneysel ve klinik araştırmalar yoluyla rapor edilmiştir. G. biloba L. genellikle iyi tolere edilir, ancak varfarin veya diğer antiplatelet ilaçlarla birlikte kullanıldığında kanama riskini artırabilir. Bu derleme, temel olarak G. biloba L. bitkisinin farmakolojik etkilerine ilişkin son çalışmalara odaklanmaktadır ve G. biloba L. bitkisinin nörolojik, kardiyovasküler, pulmoner, oküler, metabolik, zihinsel bozuklukların önlenmesinde ve iyileştirilmesinde faydalı olabileceğini, ayrıca antikanser ve antimikrobiyal özelliklere sahip olduğunu, ancak G. biloba L. bitkisinin güvenliğini ve etkinliğini doğrulamak ve tıbbi kullanıma geçebilmek için daha fazla araştırma ve daha ileri klinik çalışmaların gerekli olduğunu ortaya koymaktadır.

Anahtar Kelimeler: Ginkgo biloba; EGb761; ginkgolidler; ginkgolik asit; farmakolojik etkiler
REFERENCES:
  1. Page C. Ginkgoaceae. Pteridophytes and Gymnosperms. 1st ed. Berlin: Springer; 1990. p.284-9. [Crossref] 
  2. Singh B, Kaur P, Gopichand, Singh RD, Ahuja PS. Biology and chemistry of Ginkgo biloba. Fitoterapia. 2008;79(6):401-18. [Crossref]  [PubMed] 
  3. Taylor TN, Taylor EL. The Biology and Evolution of Fossil Plants. 1st ed. New Jersey: Prentice Hall; 1993.
  4. Zhou Z, Zheng S. The missing link in Ginkgo evolution. Nature. 2003;423(6942):821-2. [Crossref]  [PubMed] 
  5. Zhou Z-Y. An overview of fossil Ginkgoales. Palaeoworld. 2009;18(1):1-22. [Crossref] 
  6. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci. 2008;73(1):R14-9. [Crossref]  [PubMed] 
  7. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des. 2004;10(3):261-4. [Crossref]  [PubMed] 
  8. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci. 2003;60(9):1779-92. [Crossref]  [PubMed] 
  9. Liu L, Wang Y, Zhang J, Wang S. Advances in the chemical constituents and chemical analysis of Ginkgo biloba leaf, extract, and phytopharmaceuticals. J Pharm Biomed Anal. 2021;193:113704. [Crossref]  [PubMed] 
  10. Barbalho SM, Direito R, Laurindo LF, Marton LT, Guiguer EL, Goulart RA, et al. Ginkgo biloba in the aging process: a narrative review. Antioxidants (Basel). 2022;11(3):525. [Crossref]  [PubMed]  [PMC] 
  11. Bunyatyan N, Kovtun E, Samylina I, Stepanova E, Olefir YV, Korol L, et al. Prospects for intranasal drug delivery systems with Ginkgo biloba in the treatment of cerebral circulatory disorders. Trop J Pharm Res. 2019;18(11):2233-40. [Link] 
  12. European Medicines Agency. European Union Herbal Monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012. 2015. Cited: January 15, 2022. Available from: [Link] 
  13. Chassagne F, Huang X, Lyles JT, Quave CL. Validation of a 16th Century Traditional Chinese medicine use of Ginkgo biloba as a topical antimicrobial. Front Microbiol. 2019;10:775. [Crossref]  [PubMed]  [PMC] 
  14. Hallak B, Schneider A, Güntensperger D, Schapowal A. Standardized Ginkgo biloba extract in the treatment of vertigo and/or tinnitus: a review of the literature. Adv Aging Res. 2021;10(02):31-57. [Crossref] 
  15. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet. 1992;340(8828):1136-9. [Crossref]  [PubMed] 
  16. Shao L, Dong C, Geng D, He Q, Shi Y. Ginkgolide B protects against cognitive impairment in senescence-accelerated P8 mice by mitigating oxidative stress, inflammation and ferroptosis. Biochem Biophys Res Commun. 2021;572:7-14. [Crossref]  [PubMed] 
  17. Nash KM, Shah ZA. Current perspectives on the beneficial role of ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights. 2015;10:1-9. [Crossref]  [PubMed]  [PMC] 
  18. Yihao D, Tao G, Zhiyuan W, Xiaoming Z, Lingling D, Hongyun H. Ginkgo biloba leaf extract (EGb-761) elicits neuroprotection against cerebral ischemia/reperfusion injury by enhancement of autophagy flux in neurons in the penumbra. Iran J Basic Med Sci. 2021;24(8):1138-45. [PubMed]  [PMC] 
  19. Sun ZK, Yang HQ, Chen SD. Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's disease. Transl Neurodegener. 2013;2(1):6. [Crossref]  [PubMed]  [PMC] 
  20. Tomova T, Doncheva N, Mihaylova A, Kostadinov I, Peychev L, Argirova M. An experimental study on phytochemical composition and memory enhancing effect of Ginkgo biloba seed extract. Folia Med (Plovdiv). 2021;63(2):203-12. [Crossref]  [PubMed] 
  21. Radunz CL, Okuyama CE, Branco-Barreiro FCA, Pereira RMS, Diniz SN. Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement. Braz J Otorhinolaryngol. 2020;86(6):734-42. [Crossref]  [PubMed]  [PMC] 
  22. Barth SW, Lehner MD, Dietz GPH, Schulze H. Pharmacologic treatments in preclinical tinnitus models with special focus on Ginkgo biloba leaf extract EGb 761®. Mol Cell Neurosci. 2021;116:103669. [Crossref]  [PubMed] 
  23. Si X, Yu Z, Ren X, Huang L, Feng Y. Efficacy and safety of standardized Ginkgo biloba L. leaves extract as an adjuvant therapy for sudden sensorineural hearing loss: a systematic review and meta-analysis. J Ethnopharmacol. 2022;282:114587. [Crossref]  [PubMed] 
  24. Adebayo OG, Aduema W, Emmanuel MU, Ben-Azu B, Orji BO, Akpakpan E, et al. The anti-Parkinson potential of Gingko biloba-supplement mitigates cortico-cerebellar degeneration and neuropathobiological alterations via ınflammatory and apoptotic mediators in mice. Neurochem Res. 2022;47(8):2211-29. [Crossref]  [PubMed] 
  25. Rojas C, Rojas-Castaneda J, Ruiz-Sanchez E, Montes P, Rojas P. Antioxidant properties of a Ginkgo biloba leaf extract (EGB 761) in animal models of Alzheimer's and Parkinson's diseases. Curr Top Nutraceutical Res. 2015;13(3):105-20. [Link] 
  26. Yu D, Zhang P, Li J, Liu T, Zhang Y, Wang Q, et al. Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson's disease. J Pharm Anal. 2021;11(2):220-31. [Crossref]  [PubMed]  [PMC] 
  27. Wettstein A. Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000;6(6):393-401. [Crossref]  [PubMed] 
  28. Wang J, Chen X, Bai W, Wang Z, Xiao W, Zhu J. Study on Mechanism of Ginkgo biloba L. leaves for the treatment of neurodegenerative diseases based on network pharmacology. Neurochem Res. 2021;46(7):1881-94. [Crossref]  [PubMed] 
  29. Liu H, Ye M, Guo H. An updated review of randomized clinical trials testing the improvement of cognitive function of Ginkgo biloba extract in healthy people and Alzheimer's patients. Front Pharmacol. 2020;10:1688. [Crossref]  [PubMed]  [PMC] 
  30. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(6):716-23. [Crossref]  [PubMed] 
  31. Spiegel R, Kalla R, Mantokoudis G, Maire R, Mueller H, Hoerr R, et al. Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials. Clin Interv Aging. 2018;13:1121-7. [Crossref]  [PubMed]  [PMC] 
  32. Eisvand F, Razavi BM, Hosseinzadeh H. The effects of Ginkgo biloba on metabolic syndrome: a review. Phytother Res. 2020;34(8):1798-811. [Crossref]  [PubMed] 
  33. Liang H, Yuan X, Sun C, Sun Y, Yang M, Feng S, et al. Preparation of a new component group of Ginkgo biloba leaves and investigation of the antihypertensive effects in spontaneously hypertensive rats. Biomed Pharmacother. 2022;149:112805. [Crossref]  [PubMed] 
  34. Okipniak I, Ilashchuk T, Bachuk-Ponych N. A11847 Ginkgo biloba influence on blood pressure in patients with arterial hypertension. J Hypertens. 2018;36:e206. [Crossref] 
  35. Noor-E-Tabassum, Das R, Lami MS, Chakraborty AJ, Mitra S, Tallei TE, et al. Ginkgo biloba: a treasure of functional phytochemicals with multimedicinal applications. Evid Based Complement Alternat Med. 2022;2022:8288818. [Crossref]  [PubMed]  [PMC] 
  36. Shu Z, Hussain Sh A, Shahen M, Wang H, Alagawany M, Abd El-Hac ME, et al. Pharmacological uses of Ginkgo biloba extracts for cardiovascular disease and coronary heart diseases. Int J Pharmacol. 2018;15(1):1-9. [Crossref] 
  37. Fan Y, Jin X, Man C, Gong D. Does adjuvant treatment with ginkgo biloba to statins have additional benefits in patients with dyslipidemia? Front Pharmacol. 2018;9:659. [Crossref]  [PubMed]  [PMC] 
  38. Chong PZ, Ng HY, Tai JT, Lee SWH. Efficacy and safety of Ginkgo biloba in patients with acute ischemic stroke: a systematic review and meta-analysis. Am J Chin Med. 2020;48(3):513-34. [Crossref]  [PubMed] 
  39. Luo C, Fan LH, Zhang H, Zhao J, Li L, Zhang L, et al. Effects of ginkgo biloba extract on the cognitive function and expression profile of inflammatory factors in a rat model of hemorrhagic stroke. Neuroreport. 2018;29(15):1239-43. [Crossref]  [PubMed] 
  40. Zeng X, Liu M, Yang Y, Li Y, Asplund K. Ginkgo biloba for acute ischaemic stroke. Cochrane Database Syst Rev. 2005;2005(4):CD003691. [Crossref]  [PubMed]  [PMC] 
  41. Zhao S, Zheng H, Du Y, Zhang R, Chen P, Ren R, et al. The clinical efficacy of Ginkgo biloba leaf preparation on ischemic stroke: a systematic review and meta-analysis. Evid based complement Alternat Med. 2021;2021:4265219. [Crossref]  [PubMed]  [PMC] 
  42. Babayigit A, Olmez D, Karaman O, Ozogul C, Yilmaz O, Kivcak B, et al. Effects of Ginkgo biloba on airway histology in a mouse model of chronic asthma. Allergy Asthma Proc. 2009;30(2):186-91. [Crossref]  [PubMed] 
  43. Huang P, Zhang L, Chai C, Qian XC, Li W, Li JS, et al. Effects of food and gender on the pharmacokinetics of ginkgolides A, B, C and bilobalide in rats after oral dosing with ginkgo terpene lactones extract. J Pharm Biomed Anal. 2014;100:138-44. [Crossref]  [PubMed] 
  44. Ke J, Li MT, Huo YJ, Cheng YQ, Guo SF, Wu Y, et al. The synergistic effect of Ginkgo biloba extract 50 and aspirin against platelet aggregation. Drug Des Devel Ther. 2021;15:3543-60. [Crossref]  [PubMed]  [PMC] 
  45. Lou C, Lu H, Ma Z, Liu C, Zhang Y. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway. Biomed Pharmacother. 2019;109:563-72. [Crossref]  [PubMed] 
  46. Shang Q, Zhou X, Yang MR, Lu JG, Pan Y, Zhu GY, et al. Amide derivatives of Ginkgolide B and their inhibitory effects on PAF-induced platelet aggregation. ACS Omega. 2021;6(35):22497-503. [Crossref]  [PubMed]  [PMC] 
  47. Tao Z, Jin W, Ao M, Zhai S, Xu H, Yu L. Evaluation of the anti-inflammatory properties of the active constituents in Ginkgo biloba for the treatment of pulmonary diseases. Food Funct. 2019;10(4):2209-20. [Crossref]  [PubMed] 
  48. Ibrahim MA, Ramadan HH, Mohammed RN. Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections. J Basic Clin Physiol Pharmacol. 2021;32(3):131-43. [Crossref]  [PubMed] 
  49. Xiong Y, Zhu GH, Wang HN, Hu Q, Chen LL, Guan XQ, et al. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CLpro from Ginkgo biloba leaves via large-scale screening. Fitoterapia. 2021;152:104909. [Crossref]  [PubMed]  [PMC] 
  50. Labkovich M, Jacobs EB, Bhargava S, Pasquale LR, Ritch R. Ginkgo Biloba extract in ophthalmic and systemic disease, with a focus on normal-tension glaucoma. Asia Pac J Ophthalmol (Phila). 2020;9(3):215-25. [Crossref]  [PubMed]  [PMC] 
  51. Martínez-Solís I, Acero N, Bosch-Morell F, Castillo E, González-Rosende ME, Mu-oz-Mingarro D, et al. Neuroprotective potential of Ginkgo biloba in retinal diseases. Planta Med. 2019;85(17):1292-303. [Crossref]  [PubMed] 
  52. Chudhary M, Zhang C, Song S, Ren X, Kong L. Ginkgo biloba delays light-induced photoreceptor degeneration through antioxidant and antiapoptotic properties. Exp Ther Med. 2021;21(6):576. [Crossref]  [PubMed]  [PMC] 
  53. Ige M, Liu J. Herbal medicines in glaucoma treatment. Yale J Biol Med. 2020;93(2):347-53. [PubMed]  [PMC] 
  54. Sabaner MC, Dogan M, Altin SS, Balaman C, Yilmaz C, Omur A, et al. Ginkgo Biloba affects microvascular morphology: a prospective optical coherence tomography angiography pilot study. Int Ophthalmol. 2021;41(3):1053-61. [Crossref]  [PubMed] 
  55. Kang JM, Lin S. Ginkgo biloba and its potential role in glaucoma. Curr Opin Ophthalmol. 2018;29(2):116-20. [Crossref]  [PubMed] 
  56. Okhti Z, Abdalah ME, Basil D. Phytochemical structure and biological effect of Ginkgo biloba leaves: a review. Int J Pharm Res. 2021;13:1138-43. [Crossref] 
  57. Chang L, Liu T, Chai Z, Jie S, Li Z, Liu M, et al. lincRNA-p21 mediates the anti-cancer effect of ginkgo biloba extract EGb 761 by stabilizing e-cadherin protein in colon cancer. Med Sci Monit. 2018;24:9488-96. [Crossref]  [PubMed]  [PMC] 
  58. Yiling X, Qingfeng M, Dejun C, Qing Y, Wei Z. Effects of ginkgolide B on the proliferation and apoptosis of cervical cancer cells. Curr Top Nutraceutical Res. 2020;18(3):227-32. [Crossref] 
  59. Arannilewa AJ, Suleiman Alakanse O, Adesola AO, Israel Malachi O, Michael Obaidu I, Oluwafemi EE, et al. Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target. Bioinformation. 2018;14(9):482-7. [Crossref]  [PubMed]  [PMC] 
  60. Wang X, Shao QH, Zhou H, Wu JL, Quan WQ, Ji P, et al. Ginkgolide B inhibits lung cancer cells promotion via beclin-1-dependent autophagy. BMC Complement Med Ther. 2020;20(1):194. [Crossref]  [PubMed]  [PMC] 
  61. Zuo W, Yan F, Zhang B, Li J, Mei D. Advances in the studies of ginkgo biloba leaves extract on aging-related diseases. Aging Dis. 2017;8(6):812-26. [Crossref]  [PubMed]  [PMC] 
  62. Aziz TA, Hussain SA, Mahwi TO, Ahmed ZA, Rahman HS, Rasedee A. The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial. Drug Des Devel Ther. 2018;12:735-42. [Crossref]  [PubMed]  [PMC] 
  63. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472-80. [Crossref]  [PubMed] 
  64. Alsmadi AM, Tawalbeh LI, Gammoh OS, Shawagfeh MQ, Zalloum W, Ashour A, et al. The effect of Ginkgo biloba and psycho-education on stress, anxiety and fatigue among refugees. Proc Singap Healthc. 2018;27(1):26-32. [Crossref] 
  65. Sati P, Dhyani P, Bhatt ID, Pandey A. Ginkgo biloba flavonoid glycosides in antimicrobial perspective with reference to extraction method. J Tradit Complement Med. 2018;9(1):15-23. [Crossref]  [PubMed]  [PMC] 
  66. Ražná K, Sawinska Z, Ivani?ová E, Vukovic N, Terentjeva M, Stričík M, et al. Properties of Ginkgo biloba L.: antioxidant characterization, antimicrobial activities, and genomic microrna based marker fingerprints. Int J Mol Sci. 2020;21(9):3087. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com